Actively Recruiting
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Led by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology · Updated on 2024-08-28
15
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.
CONDITIONS
Official Title
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with primary high risk AML
- Diagnosed with primary refractory AML
- Diagnosed with relapsed AML
- Karnofsky or Lansky performance scale score of 70 or higher
- Written informed consent obtained
- Haploidentical family donor available
- Donor suitable for cell donation and apheresis by standard criteria
- Donor provides written informed consent
You will not qualify if you...
- Presence of uncontrolled infection
- Severe liver dysfunction with SGOT or SCPT 5 times or more above normal for age
- Positive serology for human immunodeficiency virus (HIV) in patient
- Donor is pregnant
- Donor has positive serology for HIV, hepatitis B, or hepatitis C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk, Minsk Oblast, Belarus, 223053
Actively Recruiting
Research Team
T
Tatsiana Shman, PhD
CONTACT
M
Mariya Naumovich, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here